Consistent with the findings of our proteomics analysis, in the validation cohort we found that serum and CSF IGFBP7 levels in the MS group and NMOSD group were significantly higher than those in the controls, with the MS group exhibiting a greater increase than the NMOSD group. This evidence concerns the gene IGFBP7 and myeloid sarcoma.